We claim:

1. (currently amended) A compound of the formula I,



I

wherein

R1 and R2 are each independently H, O-(C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl or (C_1-C_6)-alkyl, wherein said (C_1-C_6)-alkyl is optionally substituted by OH, O-(C_1-C_4)-alkyl, NH_2, NH(C_1-C_4)-alkyl or N[(C_1-C_6)-alkyl]$_2$;

R3 and R4 are each independently F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, O-(C_2-C_6)-alkenyl or (C_2-C_6)-alkynyl, wherein said (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, O-(C_2-C_6)-alkenyl and (C_2-C_6)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

R5 is H, F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_0-C_6)-alkylene-COO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl or (C_2-C_6)-alkynyl, wherein said (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_0-C_6)-alkylene-COO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl and (C_2-C_6)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

A is H, F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, O-(C_1-C_6)-alkyl, S(O)$_{1,2}$-(C_1-C_6)-alkyl-, NH-(C_1-C_6)-alkyl, N-[(C_1-C_6)-alkyl]$_2$, ~~COOH,~~ COO-(C_1-C_6)-alkyl, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-[(C_1-C_6)-alkyl]$_2$, SO_2NH_2, SO_2NH-(C_1-C_6)-alkyl, SO_2N-[(C_1-C_6)-alkyl]$_2$ or NHCOR6, wherein

PAGE 4/18 * RCVD AT 5/17/2005 2:11:44 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:908 231 2626 * DURATION (mm-ss):04-56

said (C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, O-(C_1-C_6)-alkyl, $S(O)_{1-2}$-(C_1-C_6)-alkyl-, NH-(C_1-C_6)-alkyl, N-$[(C_1-C_6)$-alkyl$]_2$, COO-(C_1-C_6)-alkyl, CONH-(C_1-C_6)-alkyl, CON-$[(C_1-C_6)$-alkyl$]_2$, SO_2NH-(C_1-C_6)-alkyl and SO_2N-$[(C_1-C_6)$-alkyl$]_2$ are optionally mono- or polysubstituted by F, Cl, Br, ~~COOH,~~ COO-(C_1-C_6)-alkyl, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON$[(C_1-C_6)$-alkyl$]_2$ or OCO-(C_1-C_6)-alkyl;

R6 is H, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkylene, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-$CONH_2$, (C_6-C_{10})-aryl, (C_1-C_4)-alkylene-(C_6-C_{10})-aryl, heteroaryl, (C_1-C_4)-alkylene-heteroaryl or CO-heteroaryl, wherein said (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkylene, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH and (C_1-C_6)-alkylene-$CONH_2$ are optionally mono- or polysubstituted by F, Cl, Br, O$(C_1-C_4$-alkyl), COO-$(C_1-C_4$-alkyl) or N-$[(C_1-C_4)$-alkyl$]_2$ and said (C_6-C_{10})-aryl, (C_1-C_4)-alkylene-(C_6-C_{10})-aryl, heteroaryl, (C_1-C_4)-alkylene-heteroaryl and CO-heteroaryl are optionally mono- or polysubstituted by F, Cl, Br, NO_2, CN, O-$(C_1-C_4$-alkyl), S-COO$(C_1-C_4$-alkyl), COO-$(C_1-C_4$-alkyl), N-$[(C_1-C_4)$-alkyl$]_2$ or (C_1-C_6)-alkyl;

n is 0, 1, 2 or 3;

m is 1, 2, 3, 4 or 5;

o is 0, 1, 2 or 3;

Het is a heterocyclic 4- to 7-membered ring which may contain up to four N, O or S heteroatoms and wherein said heterocyclic 4- to 7-membered ring is optionally substituted by R7, R8 and R9, with the proviso that said heterocyclic 4- to 7-membered ring cannot be pyrrole; and

R7, R8, and R9 are each independently H, F, Cl, Br, (C_1-C_6)-alkyl, O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl, O-(C_2-C_6)-alkynyl, OH, oxo, O-(C_1-C_6)-alkyl, NH_2, NH-(C_1-C_6)-alkyl, N-$[(C_1-C_6)$-alkyl$]_2$, COOH, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-$[(C_1-C_6)$-alkyl$]_2$, (C_0-C_6)-alkylene-aryl or (C_1-C_6)-alkylene-COO-$(C_1-$

PAGE 5/18 * RCVD AT 5/17/2005 2:11:44 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:908 231 2626 * DURATION (mm-ss):04-56

C_6)-alkyl, wherein said (C_1-C_6)-alkyl, O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl, O-(C_2-C_6)-alkynyl, O-(C_1-C_6)-alkyl, NH-(C_1-C_6)-alkyl, N-[(C_1-C_6)-alkyl]$_2$, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, CONH-(C_1-C_6)-alkyl, CON-[(C_1-C_6)-alkyl]$_2$, (C_0-C_6)-alkylene-aryl and (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl are optionally substituted by COOH, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-[(C_1-C_6)-alkyl]$_2$, OCO-(C_1-C_6)-alkyl, F, Cl, (C_1-C_6)-alkyl or O-(C_1-C_6)-alkyl;
and two radicals selected from said R7, R8 and R9 may optionally be bonded together to form a ring fused onto said heterocyclic 4- to 7-membered ring;

and pharmaceutically acceptable salts thereof.

2. (currently amended) The compound of Claim 1 wherein

R1 and R2 are H;

R3 and R4 are each independently F, Cl or Br;

R5 is H, F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_0-C_6)-alkylene-COO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl or (C_2-C_6)-alkynyl, wherein said (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_0-C_6)-alkylene-COO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl and (C_2-C_6)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

A is H, F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, O-(C_1-C_6)-alkyl, S(O)$_{1-2}$-(C_1-C_6)-alkyl-, NH-(C_1-C_6)-alkyl, N-[(C_1-C_6)-alkyl]$_2$, ~~COOH,~~ COO-(C_1-C_6)-alkyl, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-[(C_1-C_6)- alkyl]$_2$, SO_2NH_2, SO_2NH-(C_1-C_6)-alkyl, SO_2N-[(C_1-C_6)-alkyl]$_2$ or NHCOR6, wherein said (C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, O-(C_1-C_6)-alkyl, S(O)$_{1-2}$-(C_1-C_6)-alkyl-, NH-(C_1-C_6)-alkyl, N-[(C_1-C_6)-alkyl]$_2$, COO-(C_1-C_6)-alkyl, CONH-(C_1-C_6)-alkyl, CON-[(C_1-C_6)- alkyl]$_2$, SO_2NH-(C_1-C_6)-alkyl and SO_2N-[(C_1-C_6)-alkyl]$_2$ are optionally mono- or polysubstituted by F, Cl, Br, ~~COOH,~~ COO-(C_1-C_6)-alkyl, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-[(C_1-C_6)-alkyl]$_2$ or OCO-(C_1-C_6)-alkyl;

PAGE 6/18 * RCVD AT 5/17/2005 2:11:44 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:908 231 2626 * DURATION (mm-ss):04-56

R6 is H, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkylene, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-$CONH_2$, (C_6-C_{10})-aryl, (C_1-C_4)-alkylene-(C_6-C_{10})-aryl, heteroaryl, (C_1-C_4)-alkylene-heteroaryl or CO-heteroaryl, wherein said (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkylene, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH and (C_1-C_6)-alkylene-$CONH_2$ are optionally mono- or polysubstituted by F, Cl, Br, O-(C_1-C_4)-alkyl, COO-$(C_1-C_4$-alkyl), or N-$[(C_1-C_4)$-alkyl$]_2$, and said (C_6-C_{10})-aryl, (C_1-C_4)-alkylene-(C_6-C_{10})-aryl, heteroaryl, (C_1-C_4)-alkylene-heteroaryl and CO-heteroaryl are optionally mono- or polysubstituted by F, Cl, Br, NO_2, CN, O-$(C_1-C_4$-alkyl), COO-$(C_1-C_4$-alkyl), S-COO$(C_1-C_4$-alkyl), N-$[(C_1-C_4)$-alkyl$]_2$ or (C_1-C_6)-alkyl;

n is 0, 1 or 2;

m is 1;

o is 0 or 1;

Het is a heterocyclic 4- to 7-membered ring selected from triazolyl, tetrazolyl, oxadiazolyl, pyrazolyl, benzimidazolyl, furyl, triazinyl or  wherein said heterocyclic 4- to 7-membered ring is optionally substituted by R7, R8 and R9; and

R7, R8, and R9 are each independently H, F, Cl, Br, (C_1-C_6)-alkyl , O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl, O-(C_2-C_6)-alkynyl, OH, oxo, O-(C_1-C_6)-alkyl, NH_2, NH-(C_1-C_6)-alkyl, N-$[(C_1-C_6)$-alkyl$]_2$, COOH, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-$[(C_1-C_6)$-alkyl$]_2$, (C_0-C_6)-alkylene-aryl or (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl, wherein said (C_1-C_6)-alkyl , O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl, O-(C_2-C_6)-alkynyl, O-(C_1-C_6)-alkyl, NH-(C_1-C_6)-alkyl, N-$[(C_1-C_6)$-alkyl$]_2$, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, CONH-(C_1-C_6)-alkyl, CON-$[(C_1-C_6)$-alkyl$]_2$, (C_0-C_6)-alkylene-aryl and (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl are optionally substituted by COOH, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-$[(C_1-C_6)$-alkyl$]_2$, OCO-(C_1-C_6)-alkyl, F, Cl, (C_1-C_6)-alkyl or O-(C_1-C_6)-alkyl;

PAGE 7/18 * RCVD AT 5/17/2005 2:11:44 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:908 231 2626 * DURATION (mm-ss):04-56

and two radicals selected from said R7, R8 and R9 may optionally be bonded together to form a ring fused onto said heterocyclic 4- to 7-membered ring;

and pharmaceutically acceptable salts thereof.

3. (original) The compound of Claim 2 wherein

R1 and R2 are H;

R3 and R4 are each independently F, Cl or Br;

R5 is H, F, Cl, Br, OH, NO_2, CN, $(C_1$-$C_6)$-alkyl, O-$(C_1$-$C_4)$-alkyl, CO-$(C_1$-$C_6)$-alkyl, $(C_0$-$C_6)$-alkylene-COOH, $(C_0$-$C_6)$-alkylene-COO-$(C_1$-$C_6)$-alkyl, SO_2-$(C_1$-$C_6)$-alkyl, O-$(C_2$-$C_6)$-alkenyl or $(C_2$-$C_6)$-alkynyl, wherein said $(C_1$-$C_6)$-alkyl, O-$(C_1$-$C_4)$-alkyl, CO-$(C_1$-$C_6)$-alkyl, $(C_0$-$C_6)$-alkylene-COOH, $(C_0$-$C_6)$-alkylene-COO-$(C_1$-$C_6)$-alkyl, SO_2-$(C_1$-$C_6)$-alkyl, O-$(C_2$-$C_6)$-alkenyl and $(C_2$-$C_6)$-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

A is H, F, Cl, Br, $(C_1$-$C_6)$-alkyl, CF_3, OCF_3, NO_2, CN, O-$(C_1$-$C_6)$-alkyl, CO-$(C_1$-$C_6)$-alkyl, $(C_0$-$C_6)$-alkylene-COOH, $(C_0$-$C_6)$-alkylene-COO-$(C_1$-$C_6)$-alkyl or SO_2-$(C_1$-$C_6)$-alkyl;

n is 0, 1 or 2;

m is 1;

o is 0 or 1;

Het is a heterocyclic 4- to 7-membered ring group selected from triazolyl, tetrazolyl, oxadiazolyl, furyl, triazinyl or  , wherein said 4- to 7-membered heterocyclic ring is optionally substituted by R7, R8 and R9; and

R7, R8, and R9 are each independently H, $(C_1$-$C_6)$-alkyl, OH, oxo, NH_2, COOH, COO-$(C_1$-$C_6)$-alkyl, $CONH_2$, CONH-$(C_1$-$C_6)$-alkyl or CON-$[(C_1$-$C_6)$-alkyl$]_2$, wherein said $(C_1$-$C_6)$-alkyl,

PAGE 8/18 * RCVD AT 5/17/2005 2:11:44 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:908 231 2626 * DURATION (mm-ss):04-56

$COO-(C_1-C_6)$-alkyl, $CONH-(C_1-C_6)$-alkyl and $CON-[(C_1-C_6)\text{-alkyl}]_2$ are optionally substituted by COOH;

and pharmaceutically acceptable salts thereof.

4. (original) The compound of Claim 1 wherein the compound has the structure Ia



Ia

wherein

R5 is H, F, Cl, Br, (C_1-C_6)-alkyl, CF_3, OCF_3, NO_2, CN, $O-(C_1-C_6)$-alkyl, $CO-(C_1-C_6)$-alkyl, (C_0-C_6)-alkylene-COOH, (C_0-C_6)-alkylene–$COO-(C_1-C_6)$-alkyl or $SO_2-(C_1-C_6)$-alkyl;

A is H, F, Cl, Br, (C_1-C_6)-alkyl, CF_3, OCF_3, NO_2, CN, $O-(C_1-C_6)$-alkyl, $CO-(C_1-C_6)$-alkyl, (C_0-C_6)-alkylene-COOH, (C_0-C_6)-alkylene–$COO-(C_1-C_6)$-alkyl or $SO_2-(C_1-C_6)$-alkyl;

R7 is H, (C_1-C_6)-alkyl, (C_0-C_6)-alkylene-aryl, $O-(C_1-C_6)$-alkyl, $O-(C_2-C_6)$-alkenyl or $O-(C_2-C_6)$-alkynyl, wherein said (C_1-C_6)-alkyl, (C_0-C_6)-alkylene-aryl, $O-(C_1-C_6)$-alkyl, $O-(C_2-C_6)$-alkenyl and $O-(C_2-C_6)$-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

R8 is -(C=O)-X;

X is OH, $O-(C_1-C_6)$-alkyl, NH_2, $NH-(C_1-C_6)$-alkyl or $N-((C_1-C_6)\text{-alkyl})_2$;

PAGE 9/18 * RCVD AT 5/17/2005 2:11:44 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:908 231 2626 * DURATION (mm-ss):04-56

m is 1 or 2; and

n is 1 or 2;

and pharmaceutically acceptable salts thereof.

5. (currently amended) The compound of Claim 1 wherein the compound has the structure Iaa



Iaa

wherein

R5 is H or F;

A is H, F, Cl, $(C_1$-$C_6)$-alkyl, CF_3, COO-$(C_1$-$C_6)$-alkyl, ~~COOH~~ or SO_2-$(C_1$-$C_6)$-alkyl;

R7 is H or phenyl;

R8 is -(C=O)-X; and

X is OH, O-$(C_1$-$C_6)$-alkyl, NH_2, NH-$(C_1$-$C_6)$-alkyl or N-$[(C_1$-$C_6)$-alkyl$]_2$;

and pharmaceutically acceptable salts thereof.

6. (original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of Claim 1.

7. (currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of Claim 1 and at least one further active ingredient.

PAGE 10/18 * RCVD AT 5/17/2005 2:11:44 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:908 231 2626 * DURATION (mm-ss):04-56

8. (original) The pharmaceutical composition of Claim 7, wherein said further active ingredient is selected from the group consisting of:
antidiabetics, hypoglycemic active ingredients, HMG-CoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, CETP inhibitors, polymeric bile acid adsorbents, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP-citrate-lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, lipase inhibitors, insulins, sulfonylureas, biguanides, meglitinides, thiazolidinediones, α-glucosidase inhibitors, active ingredients acting on the ATP-dependent potassium channel of the beta cells, CART agonists, NPY agonists, MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists, β3 agonists, MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin reuptake inhibitors, mixed serotoninergic and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone-releasing compounds, TRH agonists, uncoupling protein 2 or 3 modulators, leptin agonists, DA agonists (bromocriptine, Doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR-β agonists or amphetamines.

9. (original) A method of reducing blood sugar comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

10. (original) A method for treating lipid and carbohydrate metabolism disorders comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

11. (original) A method for treating type 2 diabetes comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

12. (original) A method for treating arteriosclerotic symptoms comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

13. (original) A method for treating insulin resistance comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

PAGE 11/18 * RCVD AT 5/17/2005 2:11:44 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:908 231 2626 * DURATION (mm-ss):04-56

14. (currently amended) A process for preparing a compound of Claim 1, which comprises reacting a urea of formula 2 with a compound of formula 4



2



4

wherein

R1 and R2 are each independently H, O-(C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl or (C_1-C_6)-alkyl, wherein said (C_1-C_6)-alkyl is optionally substituted by OH, O-(C_1-C_4)-alkyl, NH_2, $NH(C_1$-$C_4)$-alkyl or $N[(C_1$-$C_6)$-alkyl$]_2$;

R3 and R4 are each independently F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, O-(C_2-C_6)-alkenyl or (C_2-C_6)-alkynyl, wherein said (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, O-(C_2-C_6)-alkenyl and (C_2-C_6)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

R5 is H, F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_0-C_6)-alkylene-COO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl or (C_2-C_6)-alkynyl, wherein said (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_0-C_6)-alkylene-COO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl and (C_2-C_6)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

A is H, F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, O-(C_1-C_6)-alkyl, $S(O)_{1-2}$-(C_1-C_6)-alkyl-, NH-(C_1-C_6)-alkyl, N-[(C_1-C_6)-alkyl$]_2$, ~~COOH,~~ COO-(C_1-C_6)-alkyl, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-[(C_1-C_6)-alkyl$]_2$, SO_2NH_2, SO_2NH-(C_1-C_6)-alkyl, SO_2N-[(C_1-C_6)-alkyl$]_2$ or NHCOR6, wherein said (C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, O-(C_1-C_6)-alkyl, $S(O)_{1-2}$-(C_1-C_6)-alkyl-, NH-(C_1-C_6)-alkyl, N-[(C_1-C_6)-alkyl$]_2$, COO-(C_1-C_6)-

PAGE 12/18 * RCVD AT 5/17/2005 2:11:44 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:908 231 2626 * DURATION (mm-ss):04-56

alkyl, CONH-(C_1-C_6)-alkyl, CON-[(C_1-C_6)-alkyl]$_2$, SO_2NH-(C_1-C_6)-alkyl and SO_2N-[(C_1-C_6)-alkyl]$_2$ are optionally mono- or polysubstituted by F, Cl, Br, ~~COOH,~~ COO-(C_1-C_6)-alkyl, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON[(C_1-C_6)-alkyl]$_2$ or OCO-(C_1-C_6)-alkyl;

n is 0, 1, 2 or 3;

R7 and R8 are each independently H, F, Cl, Br, (C_1-C_6)-alkyl, O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl, O-(C_2-C_6)-alkynyl, OH, oxo, O-(C_1-C_6)-alkyl, NH_2, NH-(C_1-C_6)-alkyl, N-[(C_1-C_6)-alkyl]$_2$, COOH, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-[(C_1-C_6)-alkyl]$_2$, (C_0-C_6)-alkylene-aryl or (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl, wherein said (C_1-C_6)-alkyl, O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl, O-(C_2-C_6)-alkynyl, O-(C_1-C_6)-alkyl, NH-(C_1-C_6)-alkyl, N-[(C_1-C_6)-alkyl]$_2$, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, CONH-(C_1-C_6)-alkyl, CON-[(C_1-C_6)-alkyl]$_2$, (C_0-C_6)-alkylene-aryl and (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl are optionally substituted by COOH, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-[(C_1-C_6)-alkyl]$_2$, OCO-(C_1-C_6)-alkyl, F, Cl, (C_1-C_6)-alkyl or O-(C_1-C_6)-alkyl;
and said R7 and R8 may optionally be bonded together to form a ring fused onto said heterocyclic 4- to 7-membered ring; and

Y is Cl or



15. (currently amended) A process for preparing a compound of Claim 1, which comprises reacting an aniline derivative of formula 3 with a compound of formula 4



3



4

wherein

PAGE 13/18 * RCVD AT 5/17/2005 2:11:44 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:908 231 2626 * DURATION (mm-ss):04-56

R2 is H, O-(C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl or (C_1-C_6)-alkyl, wherein said (C_1-C_6)-alkyl is optionally substituted by OH, O-(C_1-C_4)-alkyl, NH_2, NH(C_1-C_4)-alkyl or N[(C_1-C_6)-alkyl]$_2$;

R3 and R4 are each independently F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, O-(C_2-C_6)-alkenyl or (C_2-C_6)-alkynyl, wherein said (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, O-(C_2-C_6)-alkenyl and (C_2-C_6)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

R5 is H, F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_0-C_6)-alkylene-COO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl or (C_2-C_6)-alkynyl, wherein said (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_0-C_6)-alkylene-COO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl and (C_2-C_6)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

A is H, F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, O-(C_1-C_6)-alkyl, S(O)$_{1-2}$-(C_1-C_6)-alkyl-, NH-(C_1-C_6)-alkyl, N-[(C_1-C_6)-alkyl]$_2$, ~~COOH,~~ COO-(C_1-C_6)-alkyl, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-[(C_1-C_6)-alkyl]$_2$, SO_2NH_2, SO_2NH-(C_1-C_6)-alkyl, SO_2N-[(C_1-C_6)-alkyl]$_2$ or NHCOR6, wherein said (C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, O-(C_1-C_6)-alkyl, S(O)$_{1-2}$-(C_1-C_6)-alkyl-, NH-(C_1-C_6)-alkyl, N-[(C_1-C_6)-alkyl]$_2$, COO-(C_1-C_6)-alkyl, CONH-(C_1-C_6)-alkyl, CON-[(C_1-C_6)-alkyl]$_2$, SO_2NH-(C_1-C_6)-alkyl and SO_2N-[(C_1-C_6)-alkyl]$_2$ are optionally mono- or polysubstituted by F, Cl, Br, ~~COOH,~~ COO-(C_1-C_6)-alkyl, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON[(C_1-C_6)-alkyl]$_2$ or OCO-(C_1-C_6)-alkyl;

n is 0, 1, 2 or 3;

R7 and R8 are each independently H, F, Cl, Br, (C_1-C_6)-alkyl, O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl, O-(C_2-C_6)-alkynyl, OH, oxo, O-(C_1-C_6)-alkyl, NH_2, NH-(C_1-C_6)-alkyl, N-[(C_1-C_6)-alkyl]$_2$, COOH, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-[(C_1-C_6)-alkyl]$_2$, (C_0-C_6)-alkylene-aryl or (C_1-C_6)-alkylene-COO-(C_1-

PAGE 14/18 * RCVD AT 5/17/2005 2:11:44 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:908 231 2626 * DURATION (mm-ss):04-56

C_6)-alkyl, wherein said (C_1-C_6)-alkyl, O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl, O-(C_2-C_6)-alkynyl, O-(C_1-C_6)-alkyl, NH-(C_1-C_6)-alkyl, N-[(C_1-C_6)-alkyl]$_2$, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, CONH-(C_1-C_6)-alkyl, CON-[(C_1-C_6)-alkyl]$_2$, (C_0-C_6)-alkylene-aryl and (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl are optionally substituted by COOH, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-[(C_1-C_6)-alkyl]$_2$, OCO-(C_1-C_6)-alkyl, F, Cl, (C_1-C_6)-alkyl or O-(C_1-C_6)-alkyl;

and said R7 and R8 may optionally be bonded together to form a ring fused onto said heterocyclic 4- to 7-membered ring; and

Y is –N=C=O.

PAGE 15/18 * RCVD AT 5/17/2005 2:11:44 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:908 231 2626 * DURATION (mm-ss):04-56